Clinical Trial Detail

NCT ID NCT02996825
Title Mirvetuximab Soravtansine and Gemcitabine Hydrochloride in Treating Patients With FRalpha-Positive Recurrent Ovarian, Primary Peritoneal, Fallopian Tube, Endometrial, or Triple Negative Breast Cancer
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors City of Hope Medical Center
Indications

triple-receptor negative breast cancer

endometrial cancer

ovarian cancer

fallopian tube cancer

peritoneum cancer

Therapies

Gemcitabine + Mirvetuximab Soravtansine

Age Groups: senior adult child

No variant requirements are available.